

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	PRIMA BIOMED LIMITED	(ASX:PRR)
<b>ABN</b>	90 009 237 889	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Marc Voigt
<b>Date of last notice</b>	7 January 2015

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct																								
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A																								
<b>Date of change</b>	5 August 2015																								
<b>No. of securities held prior to change</b>	<p>1) Ordinary Fully Paid Shares</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th></th> <th style="text-align: center;">Shares</th> <th style="text-align: center;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td style="text-align: right;">870,000</td> <td style="text-align: right;">1,171,754</td> </tr> <tr> <td><b>Indirect</b></td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td><b>Total</b></td> <td style="text-align: right;"><b>870,000</b></td> <td style="text-align: right;"><b>1,171,754</b></td> </tr> </tbody> </table> <p>2) American Depositary Receipts (ADR)</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th></th> <th style="text-align: center;">Shares</th> <th style="text-align: center;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td style="text-align: center;">150</td> <td style="text-align: center;">-</td> </tr> <tr> <td><b>Indirect</b></td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td><b>Total</b></td> <td style="text-align: center;"><b>150</b></td> <td style="text-align: center;">-</td> </tr> </tbody> </table> <p>3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.</p>		Shares	Options	<b>Direct</b>	870,000	1,171,754	<b>Indirect</b>	-	-	<b>Total</b>	<b>870,000</b>	<b>1,171,754</b>		Shares	Options	<b>Direct</b>	150	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>150</b>	-
	Shares	Options																							
<b>Direct</b>	870,000	1,171,754																							
<b>Indirect</b>	-	-																							
<b>Total</b>	<b>870,000</b>	<b>1,171,754</b>																							
	Shares	Options																							
<b>Direct</b>	150	-																							
<b>Indirect</b>	-	-																							
<b>Total</b>	<b>150</b>	-																							

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Ordinary Fully Paid Shares																								
<b>Number acquired</b>	<p>1) Ordinary Fully Paid Shares</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>6,666,666</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>6,666,666</b></td> <td>-</td> </tr> </tbody> </table> <p>2) 20,000,000 Performance Rights</p>		Shares	Options	<b>Direct</b>	6,666,666	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>6,666,666</b>	-												
	Shares	Options																							
<b>Direct</b>	6,666,666	-																							
<b>Indirect</b>	-	-																							
<b>Total</b>	<b>6,666,666</b>	-																							
<b>Number disposed</b>	6,666,666 Performance Rights																								
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Nil</p> <p>The Performance Rights were issued for a range of remuneration and incentive purposes in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015. No amount is payable upon exercise of the Performance Rights for shares after vesting.</p>																								
<b>No. of securities held after change</b>	<p>1) Ordinary Fully Paid Shares</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>7,536,666</td> <td>1,171,754</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>7,536,666</b></td> <td><b>1,171,754</b></td> </tr> </tbody> </table> <p>2) American Depositary Receipts (ADR)</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>150</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>150</b></td> <td>-</td> </tr> </tbody> </table> <p>3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.</p> <p>4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015.</p>		Shares	Options	<b>Direct</b>	7,536,666	1,171,754	<b>Indirect</b>	-	-	<b>Total</b>	<b>7,536,666</b>	<b>1,171,754</b>		Shares	Options	<b>Direct</b>	150	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>150</b>	-
	Shares	Options																							
<b>Direct</b>	7,536,666	1,171,754																							
<b>Indirect</b>	-	-																							
<b>Total</b>	<b>7,536,666</b>	<b>1,171,754</b>																							
	Shares	Options																							
<b>Direct</b>	150	-																							
<b>Indirect</b>	-	-																							
<b>Total</b>	<b>150</b>	-																							

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<ol style="list-style-type: none"> <li>1) 20,000,000 Performance Rights were issued in accordance with shareholder's approval obtained at the Extraordinary General Meeting on 31 July 2015. The first tranche of 6,666,666 vested immediately upon approval. After vesting of the first tranche, 13,333,334 Performance Rights remain to be vested subject to Mr Voigt meeting his service conditions over 2 subsequent annual tranches.</li> <li>2) Acquiring 6,666,666 shares upon exercise of the first tranche of performance rights. One ordinary fully paid share was acquired for each Performance Right that vested.</li> </ol>
---	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

05.08.2015

---

<sup>+</sup> See chapter 19 for defined terms.